{
    "Case ID": "",
    "Crime_Name": [
        "Patent Infringement"
    ],
    "Crime_Type": [
        "Property Crimes"
    ],
    "Dispute_Type": [
        "Patent validity and infringement"
    ],
    "Legal_Issue": [
        "Whether Novartis's patent is valid and whether Teva's generic product infringes it"
    ],
    "Governing_Law": [
        "Patent law requiring utility, non-obviousness, and sufficient disclosure"
    ],
    "Procedural_Stage": [
        "Litigation"
    ],
    "Evidence_Assessment": [
        "Expert testimonies, prior art"
    ],
    "Decision_Outcome": [
        "Novartis's compound claims upheld; use claims invalidated due to lack of demonstrated utility"
    ],
    "Burden_of_Proof": [
        "On Teva to challenge validity; on Novartis to demonstrate utility and non-obviousness"
    ],
    "Credibility_Factor": [
        "Court reliance on expert testimony and scientific evidence"
    ],
    "Legal_Rule": [
        "Utility must be demonstrated or soundly predicted; invention must be non-obvious and sufficiently disclosed"
    ],
    "Standard_of_Review": [
        "Balance of probabilities in civil patent litigation"
    ],
    "Procedural_Issue": [
        "Analysis of patent claims and compliance with statutory requirements"
    ],
    "Grounds_for_Claim": [
        "Teva alleged inutility, obviousness, and insufficiency of disclosure"
    ],
    "Outcome_on_Merits": [
        "Partial success for Novartis: compound claims valid, use claims invalid"
    ],
    "Decision_Maker": [
        "Court"
    ],
    "Judicial_Review_Outcome": [
        "Novartis succeeded on compound claims"
    ],
    "Review_Standard": [
        "Statutory interpretation and application of patent law principles"
    ],
    "Procedural_Fairness_Assessment": [
        "Fair hearing with consideration of both parties' arguments and evidence"
    ],
    "Key_Evidence_Considered": [
        "Prior art, expert testimony on utility and obviousness, patent specification"
    ],
    "Legal_Framework": [
        "National patent legislation and case law"
    ],
    "Applicant_Challenge": [
        "Teva challenged the validity of Novartis's patent"
    ],
    "Court_Result": [
        "Teva prohibited from obtaining a Notice of Compliance until patent expiry"
    ],
    "Legal_Rule_Source": [
        "Statute and judicial precedent"
    ],
    "Standard_of_Proof": [
        "Preponderance of evidence"
    ],
    "Defendant_Response": [
        "Challenged patent validity on grounds of inutility, obviousness, and insufficiency"
    ],
    "Evidence_Type": [
        "Documentary evidence, expert reports, scientific data"
    ],
    "Remedy_Requested": [
        "Teva sought approval to market generic version"
    ],
    "Outcome": [
        "Teva blocked from marketing generic until patent expiration"
    ],
    "Decision_Authority": [
        "Trial Court"
    ],
    "Remedy_Sought": [
        "Injunction against generic entry, protection of patent rights"
    ],
    "Resolution_Mechanism": [
        "Judicial determination"
    ],
    "Legal_Provision": [
        "Patent Act provisions on utility, novelty, non-obviousness, and sufficiency"
    ],
    "Authority": [
        "National patent office and courts"
    ],
    "Claimant_Status": [
        "Novartis as patent holder"
    ],
    "Legal_Provision_Cited": [
        "Requirements for utility, non-obviousness, and sufficient disclosure"
    ],
    "Grounds_for_Inadmissibility_or_Allegation": [
        "Invalidity based on lack of utility, obviousness, insufficient disclosure"
    ],
    "Applicable_Process": [
        "Patent litigation process"
    ],
    "Outcome_of_Review": [
        "Patent partially valid, infringement prevented during term"
    ],
    "Pending_Relief_or_Application": [
        "Teva's application for Notice of Compliance denied"
    ],
    "Jurisdiction": [
        "National court with jurisdiction over patent disputes"
    ],
    "Governing_Rule": [
        "Patent law rules on validity and enforcement"
    ]
}